Mizuho upgrades Boston Scientific to Buy on durable growth

Mizuho upgraded Boston Scientific to Buy from Neutral with a price target of $80, up from $65. The analyst now sees Boston Scientific as one of the more durable growth stories across the large-cap medical technology space, supported by structural market factors “along with one of the more attractive portfolios of high-growth assets.” The company’s elevated procedure volumes appear sustainable for at least the first half of 2024 and its product portfolio is attractive, the analyst tells investors in a research note. The firm says Boston Scientific is now in the “four horseman growth class in Medtech.”